Metal Drugs and the Anticancer Immune Response
Open accessThe DOI matches its Crossref record; 1,300 of the 1,300 references it cites were found in a registry or an index.
Abstract
The immune system deploys a multitude of innate and adaptive mechanisms not only to ward off pathogens but also to prevent malignant transformation ("immune surveillance"). Hence, a clinically apparent tumor already reflects selection for those malignant cell clones capable of evading immune recognition ("immune evasion"). Metal drugs, besides their well-investigated cytotoxic anticancer effects, massively interact with the cancer-immune interface and can reverse important aspects of immune evasion. This topic has recently gained intense attention based on combination approaches with anticancer immunotherapy (e.g., immune checkpoint inhibitors), a strategy recently delivering first exciting results in clinical settings. This review summarizes the promising but still extremely fragmentary knowledge on the interplay of metal drugs with the fidelity of anticancer immune responses but also their role in adverse effects. It highlights that, at least in some cases, metal drugs can induce long-lasting anticancer immune responses. Important steps in this process comprise altered visibility and susceptibility of cancer cells toward innate and adaptive immunity, as well as direct impacts on immune cell populations and the tumor microenvironment. On the basis of the gathered information, we suggest initiating joint multidisciplinary programs to implement comprehensive immune analyses into strategies to develop novel and smart anticancer metal compounds.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
2 retracted
Items 201–400 of 1,300
Yuan, Y., Hilliard, G., Ferguson, T., & Millhorn, D. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300463200 · Cited by 638
Cisplatin nephrotoxicity: a review of the literature
Manohar, S., & Leung, N. (2018) · Journal of Nephrology · doi:10.1007/s40620-017-0392-z · Cited by 636
B cell regulation in cancer and anti-tumor immunity
Sarvaria, A., Madrigal, J. A., & Saudemont, A. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.35 · Cited by 630
Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances
Revia, R. A., & Zhang, M. (2016) · Materials Today · doi:10.1016/j.mattod.2015.08.022 · Cited by 612
Evangelou, A. M. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00221-9 · Cited by 612
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy
Shalapour, S., Font-Burgada, J., Di Caro, G., Zhong, Z., Sanchez-Lopez, E., Dhar, D., Willimsky, G., Ammirante, M., Strasner, A., Hansel, D. E., et al. (2015) · Nature · doi:10.1038/nature14395 · Cited by 611
HMGB proteins: Interactions with DNA and chromatin
Štros, M. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.09.008 · Cited by 611
Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma
Rodriguez, P. C., Hernandez, C. P., Quiceno, D., Dubinett, S. M., Zabaleta, J., Ochoa, J. B., Gilbert, J., & Ochoa, A. C. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050715 · Cited by 609
Non Platinum Metal Complexes as Anti‐cancer Drugs
Ott, I., & Gust, R. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200600151 · Cited by 609
Toxicity of platinum compounds
Hartmann, J. T., & Lipp, H.-P. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.889 · Cited by 604
Deciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 598
The role of DNA mismatch repair in platinum drug resistance.
Fink, D. A., Nebel, S., Aebi, S. P., Zheng, H., Cenni, B., Nehmé, A., Christen, R. D., & Howell, S. B. (1996) · PubMed · Cited by 597
Tumor associated macrophages and neutrophils in cancer
Galdiero, M. R., Bonavita, E., Barajon, I., Garlanda, C., Mantovani, A., & Jaillon, S. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.06.003 · Cited by 597
FcRγ Activation Regulates Inflammation-Associated Squamous Carcinogenesis
Andreu, P., Johansson, M., Affara, N. I., Pucci, F., Tan, T., Junankar, S., Korets, L., Lam, J., Tawfik, D., DeNardo, D. G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.019 · Cited by 590
Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30900-2 · Cited by 590
The thioredoxin system in cancer
Arnér, E. S. J., & Holmgren, A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.10.009 · Cited by 589
Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 589
Autophagy and autophagy-related proteins in the immune system
Shibutani, S. T., Saitoh, T., Nowag, H., Münz, C., & Yoshimori, T. (2015) · Nature Immunology · doi:10.1038/ni.3273 · Cited by 582
Ferrocifen type anti cancer drugs
Jaouen, G., Vessières, A., & Top, S. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00486a · Cited by 581
Adipose Triglyceride Lipase Contributes to Cancer-Associated Cachexia
Das, S. K., Eder, S., Schauer, S., Diwoky, C., Temmel, H., Guertl, B., Gorkiewicz, G., Tamilarasan, K. P., Kumari, P., Trauner, M., et al. (2011) · Science · doi:10.1126/science.1198973 · Cited by 581
Schmid, D., Pypaert, M., & Münz, C. (2007) · Immunity · doi:10.1016/j.immuni.2006.10.018 · Cited by 577
Apetoh, L., Ghiringhelli, F., Tesniere, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J., Delaloge, S., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00573.x · Cited by 574
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Patel, S. A., & Minn, A. J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.007 · Cited by 573
Regulatory circuits of T cell function in cancer
Speiser, D. E., Ho, P.-C., & Verdeil, G. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.80 · Cited by 566
Ruthenium Complexes as Anticancer Agents
Kostova, I. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776360941 · Cited by 566
Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins
Ohndorf, U.-M., Rould, M. A., He, Q., Pabo, C. O., & Lippard, S. J. (1999) · Nature · doi:10.1038/21460 · Cited by 565
Molecular mechanisms of ATP secretion during immunogenic cell death
Martins, I., Wang, Y., Michaud, M., Ma, Y., Sukkurwala, A. Q., Shen, S., Kepp, O., Métivier, D., Galluzzi, L., Perfettini, J.-L., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.75 · Cited by 563
Discovery of IDO1 Inhibitors: From Bench to Bedside
Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2285 · Cited by 558
The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
Matlung, H. L., Szilagyi, K., Barclay, N. A., & van den Berg, T. K. (2017) · Immunological Reviews · doi:10.1111/imr.12527 · Cited by 557
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Self-citationNovel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
Arredondo, M., & Núñez, M. T. (2005) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.07.010 · Cited by 550
Jing, Y., Dai, J., Chalmers-Redman, R. M. E., Tatton, W. G., & Waxman, S. (1999) · Blood · doi:10.1182/blood.v94.6.2102 · Cited by 543
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Shree, T., Olson, O. C., Elie, B. T., Kester, J. C., Garfall, A. L., Simpson, K., Bell-McGuinn, K. M., Zabor, E. C., Brogi, E., & Joyce, J. A. (2011) · Genes & Development · doi:10.1101/gad.180331.111 · Cited by 541
Immune checkpoints and their inhibition in cancer and infectious diseases
Dyck, L., & Mills, K. H. G. (2017) · European Journal of Immunology · doi:10.1002/eji.201646875 · Cited by 541
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Li, H.-J., Du, J.-Z., Liu, J., Du, X.-J., Shen, S., Zhu, Y.-H., Wang, X., Ye, X., Nie, S., & Wang, J. (2016) · ACS Nano · doi:10.1021/acsnano.6b02326 · Cited by 537
Developing drug molecules for therapy with carbon monoxide
Romão, C. C., Blättler, W. A., Seixas, J. D., & Bernardes, G. J. L. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15317c · Cited by 524
Early immune events in the induction of allergic contact dermatitis
Kaplan, D. H., Igyártó, B. Z., & Gaspari, A. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3150 · Cited by 521
Charles F. Kettring prize. Fundamental studies with cisplatin
Rosenberg, B. (1985) · Cancer · doi:10.1002/1097-0142(19850515)55:10<2303::aid-cncr2820551002>3.0.co;2-l · Cited by 517
The potential of organometallic complexes in medicinal chemistry
Gasser, G., & Metzler-Nolte, N. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.01.013 · Cited by 516
Huang, X., Venet, F., Wang, Y. L., Lepape, A., Yuan, Z., Chen, Y., Swan, R., Kherouf, H., Monneret, G., Chung, C.-S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809422106 · Cited by 515
Approaching tumour therapy beyond platinum drugs
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.09.030 · Cited by 514
Cellular signalling of the receptor for advanced glycation end products (RAGE)
Xie, J., Méndez, J. D., Méndez-Valenzuela, V., & Aguilar-Hernández, M. M. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.06.013 · Cited by 513
Chaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 511
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies
Nobili, S., Mini, E., Landini, I., Gabbiani, C., Casini, A., & Messori, L. (2010) · Medicinal Research Reviews · doi:10.1002/med.20168 · Cited by 503
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018) · Blood · doi:10.1182/blood-2017-06-741041 · Cited by 499
Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk
Holmes, E., Li, J. V., Marchesi, J. R., & Nicholson, J. K. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.10.007 · Cited by 490
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment
Gajewski, T. F. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.011 · Cited by 488
Ruthenium Antimetastatic Agents
Alessio, E., Mestroni, G., Bergamo, A., & Sava, G. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387421 · Cited by 479
Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 478
Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Thota, S., Rodrigues, D. A., Crans, D. C., & Barreiro, E. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01689 · Cited by 476
Nanoparticle-Based Immunotherapy for Cancer
Shao, K., Singha, S., Clemente-Casares, X., Tsai, S., Yang, Y., & Santamaria, P. (2015) · ACS Nano · doi:10.1021/nn5062029 · Cited by 470
Radiotherapy and Immunogenic Cell Death
Golden, E. B., & Apetoh, L. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.005 · Cited by 463
HMGB1 release and redox regulates autophagy and apoptosis in cancer cells
Tang, D., Kang, R., Cheh, C.-W., Livesey, K. M., Liang, X., Schapiro, N. E., Benschop, R., Sparvero, L. J., Amoscato, A. A., Tracey, K. J., et al. (2010) · Oncogene · doi:10.1038/onc.2010.261 · Cited by 461
Neoantigen landscape dynamics during human melanoma–T cell interactions
Verdegaal, E. M. E., de Miranda, N. F. C. C., Visser, M., Harryvan, T., van Buuren, M. M., Andersen, R. S., Hadrup, S. R., van der Minne, C. E., Schotte, R., Spits, H., et al. (2016) · Nature · doi:10.1038/nature18945 · Cited by 461
Soriani, A., Zingoni, A., Cerboni, C., Iannitto, M. L., Ricciardi, M. R., Di Gialleonardo, V., Cippitelli, M., Fionda, C., Petrucci, M. T., Guarini, A., et al. (2009) · Blood · doi:10.1182/blood-2008-08-173914 · Cited by 460
Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T., Cho, H.-I., Antonia, S., Altiok, S., Celis, E., & Gabrilovich, D. I. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40269 · Cited by 460
Molecular aspects of tumor cell invasion and metastasis
Aznavoorian, S. A., Murphy, A. N., Stetler‐Stevenson, W. G., & Liotta, L. A. (1993) · Cancer · doi:10.1002/1097-0142(19930215)71:4<1309::aid-cncr2820710423>3.0.co;2-m · Cited by 459
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Hegde, P. S., Wallin, J. J., & Mancao, C. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.002 · Cited by 453
Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
Hato, S. V., Khong, A., de Vries, I. J. M., & Lesterhuis, W. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3141 · Cited by 451
Laurent, S., Saei, A. A., Behzadi, S., Panahifar, A., & Mahmoudi, M. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.924501 · Cited by 445
Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation
Leonard, W. J., & Spolski, R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1688 · Cited by 441
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Bergamo, A., & Sava, G. (2011) · Dalton Transactions · doi:10.1039/c0dt01816c · Cited by 440
Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
Garg, A. D., & Agostinis, P. (2017) · Immunological Reviews · doi:10.1111/imr.12574 · Cited by 440
Lu, J., Liu, X., Liao, Y.-P., Salazar, F., Sun, B., Jiang, W., Chang, C. H., Jiang, J., Wang, X., Wu, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01651-9 · Cited by 440
An Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., et al. (2012) · Science · doi:10.1126/science.1224922 · Cited by 436
The Role of Intestinal Microbiota in the Development and Severity of Chemotherapy-Induced Mucositis
van Vliet, M. J., Harmsen, H. J. M., de Bont, E. S. J. M., & Tissing, W. J. E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000879 · Cited by 436
Lazarević, T., Rilak, A., & Bugarčić, Ž. D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.007 · Cited by 428
Complement in cancer: untangling an intricate relationship
Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A., & Lambris, J. D. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.97 · Cited by 425
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Gajewski, T. F., Woo, S.-R., Zha, Y., Spaapen, R., Zheng, Y., Corrales, L., & Spranger, S. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.009 · Cited by 422
Tertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers
Dieu‐Nosjean, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Sautès‐Fridman, C. (2016) · Immunological Reviews · doi:10.1111/imr.12405 · Cited by 417
Martins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., et al. (2011) · Oncogene · doi:10.1038/onc.2010.500 · Cited by 414
Metaorganisms as the new frontier
Bosch, T. C. G., & McFall-Ngai, M. J. (2011) · Zoology · doi:10.1016/j.zool.2011.04.001 · Cited by 414
Effect of tumor cells and tumor microenvironment on NK‐cell function
Vitale, M., Cantoni, C., Pietra, G., Mingari, M. C., & Moretta, L. (2014) · European Journal of Immunology · doi:10.1002/eji.201344272 · Cited by 412
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Garg, A. D., Galluzzi, L., Apetoh, L., Baert, T., Birge, R. B., Bravo-San Pedro, J. M., Breckpot, K., Brough, D., Chaurio, R., Cirone, M., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00588 · Cited by 410
Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody
Stewart, R., Morrow, M., Hammond, S. A., Mulgrew, K., Marcus, D., Poon, E., Watkins, A., Mullins, S., Chodorge, M., Andrews, J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0191 · Cited by 409
Romagné, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D. M., Blaser, B. W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206532 · Cited by 408
Oncogenic stress sensed by the immune system: role of natural killer cell receptors
Raulet, D. H., & Guerra, N. (2009) · Nature Reviews Immunology · doi:10.1038/nri2604 · Cited by 404
Microbiota depletion promotes browning of white adipose tissue and reduces obesity
Suárez-Zamorano, N., Fabbiano, S., Chevalier, C., Stojanović, O., Colin, D. J., Stevanović, A., Veyrat-Durebex, C., Tarallo, V., Rigo, D., Germain, S., et al. (2015) · Nature Medicine · doi:10.1038/nm.3994 · Cited by 403
Adenosine Receptors: Expression, Function and Regulation
Sheth, S., Brito, R., Mukherjea, D., Rybak, L., & Ramkumar, V. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15022024 · Cited by 401
Fishelson, Z. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(03)00112-3 · Cited by 400
Xu, H., DiIulio, N. A., & Fairchild, R. L. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1001 · Cited by 400
Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury
Deng, J., Kohda, Y., Chiao, H., Wang, Y., Hu, X., Hewitt, S. M., Miyaji, T., Mcleroy, P., Nibhanupudy, B., Li, S., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00043.x · Cited by 399
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts
Chaney, S. G., Campbell, S. L., Bassett, E., & Wu, Y. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.08.008 · Cited by 396
Etiology and Pharmacology of Neuropathic Pain
Alles, S. R. A., & Smith, P. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014399 · Cited by 395
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., & Špíšek, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0950 · Cited by 392
Sawle, P., Foresti, R., Mann, B. E., Johnson, T. R., Green, C. J., & Motterlini, R. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706241 · Cited by 391
Alessio, E. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600986 · Cited by 388
Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
Enk, A. H., Jonuleit, H., Saloga, J., & Knop, J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971104)73:3<309::aid-ijc1>3.0.co;2-3 · Cited by 386
NLRC5: a key regulator of MHC class I-dependent immune responses
Kobayashi, K. S., & van den Elsen, P. J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3339 · Cited by 384
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity
Brabec, V., & Nováková, O. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.05.002 · Cited by 384
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 381
Vanadium—an element of atypical biological significance
Mukherjee, B., Patra, B., Mahapatra, S., Banerjee, P., Tiwari, A., & Chatterjee, M. (2004) · Toxicology Letters · doi:10.1016/j.toxlet.2004.01.009 · Cited by 379
TLR signaling by tumor and immune cells: a double-edged sword
Huang, B., Zhao, J., Unkeless, J. C., Feng, Z. H., & Xiong, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210904 · Cited by 377
Karki, R., Man, S. M., & Kanneganti, T.-D. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0269 · Cited by 377
Jekyll and Hyde: the role of the microenvironment on the progression of cancer
Allen, M., & Louise Jones, J. (2011) · The Journal of Pathology · doi:10.1002/path.2803 · Cited by 375
Song, W., Shen, L., Wang, Y., Liu, Q., Goodwin, T. J., Li, J., Dorosheva, O., Liu, T., Liu, R., & Huang, L. (2018) · Nature Communications · doi:10.1038/s41467-018-04605-x · Cited by 375
Leijen, S., Burgers, S. A., Baas, P., Pluim, D., Tibben, M., van Werkhoven, E., Alessio, E., Sava, G., Beijnen, J. H., & Schellens, J. H. M. (2015) · Investigational New Drugs · doi:10.1007/s10637-014-0179-1 · Cited by 374
Advances in the design of organometallic anticancer complexes
Zhang, P., & Sadler, P. J. (2017) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2017.03.038 · Cited by 369
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Vesely, M. D., & Schreiber, R. D. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12105 · Cited by 367
Honda, T., Egawa, G., Grabbe, S., & Kabashima, K. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.284 · Cited by 366
Govindan, R., Szczesna, A., Ahn, M.-J., Schneider, C.-P., Gonzalez Mella, P. F., Barlesi, F., Han, B., Ganea, D. E., Von Pawel, J., Vladimirov, V., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.7629 · Cited by 365
Percival, S. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/67.5.1064s · Cited by 364
Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection
Sheth, S., Mukherjea, D., Rybak, L. P., & Ramkumar, V. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00338 · Cited by 361
Julien, S., Merino-Trigo, A., Lacroix, L., Pocard, M., Goéré, D., Mariani, P., Landron, S., Bigot, L., Nemati, F., Dartigues, P., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0372 · Cited by 360
Risk of Leukemia after Platinum-Based Chemotherapy for Ovarian Cancer
Travis, L. B., Holowaty, E. J., Bergfeldt, K., Lynch, C. F., Kohler, B. A., Wiklund, T., Curtis, R. E., Hall, P., Andersson, M., Pukkala, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902043400504 · Cited by 359
Regulatory T Cells Suppress Innate Immunity in Kidney Ischemia-Reperfusion Injury
Kinsey, G. R., Sharma, R., Huang, L., Li, L., Vergis, A. L., Ye, H., Ju, S.-T., & Okusa, M. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008111160 · Cited by 351
Metals and metal compounds in cancer treatment.
Desoize, B. (2004) · PubMed · Cited by 349
Huang, J. C., Zamble, D. B., Reardon, J. T., Lippard, S. J., & Sancar, A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10394 · Cited by 347
Brewer, G. J., Dick, R. D., Grover, D. K., LeClaire, V., Tseng, M., Wicha, M. S., Pienta, K. J., Redman, B. G., Jahan, T. M., Sondak, V. K., et al. (2000) · PubMed · Cited by 347
Necroptosis in development and diseases
Shan, B., Pan, H., Najafov, A., & Yuan, J. (2018) · Genes & Development · doi:10.1101/gad.312561.118 · Cited by 347
Dijkgraaf, E. M., Heusinkveld, M., Tummers, B., Vogelpoel, L. T. C., Goedemans, R., Jha, V., Nortier, J. W. R., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3542 · Cited by 346
Rotte, A., Jin, J. Y., & Lemaire, V. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx686 · Cited by 344
Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
de Biasi, A. R., Villena-Vargas, J., & Adusumilli, P. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1298 · Cited by 342
Lesterhuis, W. J., Punt, C. J. A., Hato, S. V., Eleveld-Trancikova, D., Jansen, B. J. H., Nierkens, S., Schreibelt, G., de Boer, A., Van Herpen, C. M. L., Kaanders, J. H., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43656 · Cited by 340
Neuropathic pain and cytokines: current perspectives
Malcangio, M., Clark, A. K., & Old, E. A. (2013) · Journal of Pain Research · doi:10.2147/jpr.s53660 · Cited by 337
Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy
Ma, Y., Aymeric, L., Locher, C., Mattarollo, S. R., Delahaye, N. F., Pereira, P., Boucontet, L., Apetoh, L., Ghiringhelli, F., Casares, N., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100269 · Cited by 337
Platelets subvert T cell immunity against cancer via GARP-TGFβ axis
Rachidi, S., Metelli, A., Riesenberg, B., Wu, B. X., Nelson, M. H., Wallace, C., Paulos, C. M., Rubinstein, M. P., Garrett-Mayer, E., Hennig, M., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aai7911 · Cited by 335
Advances in cobalt complexes as anticancer agents
Munteanu, C. R., & Suntharalingam, K. (2015) · Dalton Transactions · doi:10.1039/c5dt02101d · Cited by 330
The critical role of GRP78 in physiologic and pathologic stress
Pfaffenbach, K. T., & Lee, A. S. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.09.007 · Cited by 327
Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance
Mapara, M. Y., & Sykes, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.041 · Cited by 325
Mehta, R. S., Nishihara, R., Cao, Y., Song, M., Mima, K., Qian, Z. R., Nowak, J. A., Kosumi, K., Hamada, T., Masugi, Y., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6374 · Cited by 325
The Challenges of Colorectal Cancer Survivorship
Denlinger, C. S., & Barsevick, A. M. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0058 · Cited by 324
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Recondo, G., Facchinetti, F., Olaussen, K. A., Besse, B., & Friboulet, L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0081-4 · Cited by 321
Roles of the NF- B Pathway in Lymphocyte Development and Function
Gerondakis, S., & Siebenlist, U. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000182 · Cited by 320
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Wu, J., & Waxman, D. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.050 · Cited by 320
TLR4 Signaling Mediates Inflammation and Tissue Injury in Nephrotoxicity
Zhang, B., Ramesh, G., Uematsu, S., Akira, S., & Reeves, W. B. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007090982 · Cited by 317
Revisiting Mouse Peritoneal Macrophages: Heterogeneity, Development, and Function
Cassado, A. D. A., D’Império Lima, M. R., & Bortoluci, K. R. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00225 · Cited by 315
Impact of the Discovery of Human Zinc Deficiency on Health
Prasad, A. S. (2009) · Journal of the American College of Nutrition · doi:10.1080/07315724.2009.10719780 · Cited by 315
The Intestinal Epithelium: Central Coordinator of Mucosal Immunity
Allaire, J. M., Crowley, S. M., Law, H. T., Chang, S.-Y., Ko, H.-J., & Vallance, B. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2018.12.008 · Cited by 315
Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy
Galluzzi, L., Bravo-San Pedro, J. M., Demaria, S., Formenti, S. C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.183 · Cited by 314
Unconventional T Cell Targets for Cancer Immunotherapy
Godfrey, D. I., Le Nours, J., Andrews, D. M., Uldrich, A. P., & Rossjohn, J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.009 · Cited by 314
Gold nanoparticles in cancer therapy
Lim, Z.-Z. J., Li, J.-E. J., Ng, C.-T., Yung, L.-Y. L., & Bay, B.-H. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.82 · Cited by 314
Local bacteria affect the efficacy of chemotherapeutic drugs
Lehouritis, P., Cummins, J., Stanton, M., Murphy, C. T., McCarthy, F. O., Reid, G., Urbaniak, C., Byrne, W. L., & Tangney, M. (2015) · Scientific Reports · doi:10.1038/srep14554 · Cited by 313
Ribonucleotide reductase: regulation, regulation, regulation
Elledge, S. J., Zhou, Z., & Allen, J. B. (1992) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(92)90249-9 · Cited by 309
Current understanding of interactions between nanoparticles and the immune system
Dobrovolskaia, M. A., Shurin, M., & Shvedova, A. A. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2015.12.022 · Cited by 309
Control of immune response by amino acid metabolism
Grohmann, U., & Bronte, V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00915.x · Cited by 308
Metal-based drugs that break the rules
Allardyce, C. S., & Dyson, P. J. (2016) · Dalton Transactions · doi:10.1039/c5dt03919c · Cited by 308
Pedersen-Bjergaard, J., Pedersen, M., Roulston, D., & Philip, P. (1995) · Blood · doi:10.1182/blood.v86.9.3542.bloodjournal8693542 · Cited by 306
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008866 · Cited by 305
Dhingra, N., Shemer, A., Correa da Rosa, J., Rozenblit, M., Fuentes-Duculan, J., Gittler, J. K., Finney, R., Czarnowicki, T., Zheng, X., Xu, H., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.03.009 · Cited by 305
ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death
Garg, A. D., Dudek, A. M., Ferreira, G. B., Verfaillie, T., Vandenabeele, P., Krysko, D. V., Mathieu, C., & Agostinis, P. (2013) · Autophagy · doi:10.4161/auto.25399 · Cited by 305
The immune system and cancer evasion strategies: therapeutic concepts
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304
Bioactive iridium and rhodium complexes as therapeutic agents
Leung, C.-H., Zhong, H.-J., Chan, D. S.-H., & Ma, D.-L. (2013) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2013.01.034 · Cited by 303
Moskowitz, C. H., Bertino, J. R., Glassman, J. R., Hedrick, E. E., Hunte, S., Coady-Lyons, N., Agus, D. B., Goy, A., Jurcic, J., Noy, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3776 · Cited by 302
Fusobacterium nucleatum in Periodontal Health and Disease
(2011) · Current Issues in Molecular Biology · doi:10.21775/cimb.013.025 · Cited by 300
The Role of the Microbiota in Inflammation, Carcinogenesis, and Cancer Therapy
Dzutsev, A., Goldszmid, R. S., Viaud, S., Zitvogel, L., & Trinchieri, G. (2015) · European Journal of Immunology · doi:10.1002/eji.201444972 · Cited by 300
Smith, R. E., Bryant, J., DeCillis, A., & Anderson, S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.114 · Cited by 300
Following TRAIL’s path in the immune system
Falschlehner, C., Schaefer, U., & Walczak, H. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03058.x · Cited by 299
Natural killer cell-mediated immunosurveillance of human cancer
Malmberg, K.-J., Carlsten, M., Björklund, A., Sohlberg, E., Bryceson, Y. T., & Ljunggren, H.-G. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.002 · Cited by 299
Paterson, B. M., & Donnelly, P. S. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00215a · Cited by 299
Oxaliplatin-related side effects: Characteristics and management
Cassidy, J., & Misset, J.-L. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)90016-3 · Cited by 298
The many “faces” of copper in medicine and treatment
Hordyjewska, A., Popiołek, Ł., & Kocot, J. (2014) · BioMetals · doi:10.1007/s10534-014-9736-5 · Cited by 298
Adhireksan, Z., Davey, G. E., Campomanes, P., Groessl, M., Clavel, C. M., Yu, H., Nazarov, A. A., Yeo, C. H. F., Ang, W. H., Dröge, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms4462 · Cited by 297
Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure
de Thé, H., Pandolfi, P. P., & Chen, Z. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.002 · Cited by 297
Wan, S., Pestka, S., Jubin, R. G., Lyu, Y. L., Tsai, Y.-C., & Liu, L. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032542 · Cited by 295
Clonal evolution of chemotherapy-resistant urothelial carcinoma
Faltas, B. M., Prandi, D., Tagawa, S. T., Molina, A. M., Nanus, D. M., Sternberg, C., Rosenberg, J., Mosquera, J. M., Robinson, B., Elemento, O., et al. (2016) · Nature Genetics · doi:10.1038/ng.3692 · Cited by 294
Pai-Scherf, L., Blumenthal, G. M., Li, H., Subramaniam, S., Mishra-Kalyani, P. S., He, K., Zhao, H., Yu, J., Paciga, M., Goldberg, K. B., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0078 · Cited by 294
Zinc: An antioxidant and anti-inflammatory agent: Role of zinc in degenerative disorders of aging
Prasad, A. S. (2014) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2014.07.019 · Cited by 293
Copper deficiency anemia: review article
Myint, Z. W., Oo, T. H., Thein, K. Z., Tun, A. M., & Saeed, H. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3407-5 · Cited by 292
Ruthenium complexes can target determinants of tumour malignancy
Bergamo, A., & Sava, G. (2007) · Dalton Transactions · doi:10.1039/b617769g · Cited by 291
B7‐H3 is a potent inhibitor of human T‐cell activation: No evidence for B7‐H3 and TREML2 interaction
Leitner, J., Klauser, C., Pickl, W. F., Stöckl, J., Majdic, O., Bardet, A. F., Kreil, D. P., Dong, C., Yamazaki, T., Zlabinger, G., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200839028 · Cited by 290
Diverse macrophages polarization in tumor microenvironment
Rhee, I. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0820-y · Cited by 290
Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator
Ishida, S., McCormick, F., Smith-McCune, K., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.011 · Cited by 288
Gut microbiota is critical for the induction of chemotherapy-induced pain
Shen, S., Lim, G., You, Z., Ding, W., Huang, P., Ran, C., Doheny, J., Caravan, P., Tate, S., Hu, K., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4606 · Cited by 286
Pabla, N., Murphy, R. F., Liu, K., & Dong, Z. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90545.2008 · Cited by 283
Giaccone, G., Bazhenova, L. A., Nemunaitis, J., Tan, M., Juhász, E., Ramlau, R., van den Heuvel, M. M., Lal, R., Kloecker, G. H., Eaton, K. D., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.035 · Cited by 279
Chemotherapy induces ATP release from tumor cells
Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J.-L., Zitvogel, L., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.22.10026 · Cited by 278
A review of the health hazards posed by cobalt
Paustenbach, D. J., Tvermoes, B. E., Unice, K. M., Finley, B. L., & Kerger, B. D. (2013) · Critical Reviews in Toxicology · doi:10.3109/10408444.2013.779633 · Cited by 278
The influence of gut microbiota on drug metabolism and toxicity
Li, H., He, J., & Jia, W. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1121234 · Cited by 278
Drug‐induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies
Lanvers‐Kaminsky, C., Zehnhoff‐Dinnesen, A. A., Parfitt, R., & Ciarimboli, G. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.603 · Cited by 277
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Garg, A. D., More, S., Rufo, N., Mece, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 276
The elements of life and medicines
Chellan, P., & Sadler, P. J. (2015) · Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences · doi:10.1098/rsta.2014.0182 · Cited by 274
Arsenic immunotoxicity: a review
Dangleben, N. L., Skibola, C. F., & Smith, M. T. (2013) · Environmental Health · doi:10.1186/1476-069x-12-73 · Cited by 274
Gallium and its competing roles with iron in biological systems
Chitambar, C. R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.04.027 · Cited by 274
Role of copper transporters in copper homeostasis
Prohaska, J. R. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.3.826s · Cited by 272
Pellegrini, C., Antonioli, L., Colucci, R., Blandizzi, C., & Fornai, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1856-5 · Cited by 270
Programmed death-1 pathway in cancer and autoimmunity
Pedoeem, A., Azoulay-Alfaguter, I., Strazza, M., Silverman, G. J., & Mor, A. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.04.010 · Cited by 268
Linder, M., Wooten, L., Cerveza, P., Cotton, S., Shulze, R., & Lomeli, N. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/67.5.965s · Cited by 267
p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice
Ramesh, G., & Reeves, W. B. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00401.2004 · Cited by 267
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
Limagne, E., Euvrard, R., Thibaudin, M., Rébé, C., Derangère, V., Chevriaux, A., Boidot, R., Végran, F., Bonnefoy, N., Vincent, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3164 · Cited by 264
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
Yamazaki, T., Hannani, D., Poirier-Colame, V, Ladoire, S., Locher, C., Sistigu, A., Prada, N., Adjemian, S., Catani, J. P., Freudenberg, M., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.72 · Cited by 262
Kumagai, Y., & Sumi, D. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105144 · Cited by 262
Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model.
Gui, Q.-F., Lu, H.-F., Zhang, C.-X., Xu, Z.-R., & Yang, Y.-H. (2015) · Genetics and Molecular Research · doi:10.4238/2015.may.25.16 · Cited by 262
Infectious and immunosuppressive complications of purine analog therapy.
Cheson, B. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2431 · Cited by 260
Zhao, X., Yang, K., Zhao, R., Ji, T., Wang, X., Yang, X., Zhang, Y., Cheng, K., Liu, S., Hao, J., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.032 · Cited by 256
Copper Compounds in Anticancer Strategies
Tardito, S., & Marchio, L. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787846532 · Cited by 255
Immunological properties of gold nanoparticles
Dykman, L. A., & Khlebtsov, N. G. (2017) · Chemical Science · doi:10.1039/c6sc03631g · Cited by 255
Chitapanarux, I., Chitapanarux, T., Traisathit, P., Kudumpee, S., Tharavichitkul, E., & Lorvidhaya, V. (2010) · Radiation Oncology · doi:10.1186/1748-717x-5-31 · Cited by 254
Makker, P. G. S., Duffy, S. S., Lees, J. G., Perera, C. J., Tonkin, R. S., Butovsky, O., Park, S. B., Goldstein, D., & Moalem-Taylor, G. (2017) · PLOS ONE · doi:10.1371/journal.pone.0170814 · Cited by 254
Inducers of immunogenic cancer cell death
Dudek, A. M., Garg, A. D., Krysko, D. V., De Ruysscher, D., & Agostinis, P. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.01.005 · Cited by 250
Ferricenium complexes: A new type of water-soluble antitumor agent
K�pf-Maier, P., K�pf, H., & Neuse, E. W. (1984) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00390468 · Cited by 248
Sekeres, M. A., Schoonen, W. M., Kantarjian, H., List, A., Fryzek, J., Paquette, R., & Maciejewski, J. P. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn349 · Cited by 248
Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90
Zhang, G., Liu, Z., Ding, H., Zhou, Y., Doan, H. A., Sin, K. W. T., Zhu, Z. J., Flores, R., Wen, Y., Gong, X., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00726-x · Cited by 248
Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy
Murugaesu, N., Wilson, G. A., Birkbak, N. J., Watkins, T. B. K., McGranahan, N., Kumar, S., Abbassi-Ghadi, N., Salm, M., Mitter, R., Horswell, S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0412 · Cited by 246
Decker, W. K., da Silva, R. F., Sanabria, M. H., Angelo, L. S., Guimarães, F., Burt, B. M., Kheradmand, F., & Paust, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00829 · Cited by 246
New B7 Family Checkpoints in Human Cancers
Ni, L., & Dong, C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0761 · Cited by 244
Resistance against novel anticancer metal compounds: Differences and similarities
Heffeter, P., Jungwirth, U., Jakupec, M., Hartinger, C., Galanski, M. S., Elbling, L., Micksche, M., Keppler, B., & Berger, W. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.02.002 · Cited by 242
Self-citation
Research works printed but not linked: 47
- van der Most R. G., 2005, Discovery Medicine, 5, 265
- Alberts B., 2015, Mol. Biol. Cell
- Seliger B., 1996, Exp. Hematol., 24, 1275
- Fink D., 1996, Cancer Res., 56, 4881
- Yoshikawa A., 1997, Kobe J. Med. Sci., 43, 109
- 10.1007/s00775-018- 1546-8 · doi:10.1007/s00775-018-
- Rosenberg, B. In Advances in Antimicrobial and Antineoplastic Chemotherapy, University Park Press: Baltimore, 1972; Vol. 11.
- 10.1002/(SICI)1098-2264(199704)18:4<286::AID-GCC6>3.0.CO;2-X · doi:10.1002/(sici)1098-2264(199704)18:4<286::aid-gcc6>3.0.co;2-x
- Dempsey J. L., 1985, Cancer Res., 45, 2873
- Nio Y., 2000, Anticancer Res., 20, 3293
- Qin X., 2010, Cell. Mol. Biol. (Noisy- le-grand), 56, 1366
- Kleinerman E. S., 1980, Cancer Res., 40, 3099
- Lichtenstein A. K., 1986, Cancer Res., 46, 639
- 10.1002/1097-0142(19930215)71:4<1313::AID-CNCR2820710424>3.0.CO;2-# · doi:10.1002/1097-0142(19930215)71:4<1313::aid-cncr2820710424>3.0.co;2-#
- Yamaue H., 1991, J. Clin. Lab. Immunol., 35, 165
- 10.1002/(SICI)1097-0215(19971104)73:3<416::AID-IJC17>3.0.CO;2-A · doi:10.1002/(sici)1097-0215(19971104)73:3<416::aid-ijc17>3.0.co;2-a
- Jiang J., 2006, Anticancer Res., 26, 2237
- Ujiie T., 1989, Jpn. J. Exp. Med., 59, 17
- Maeda K., 2011, Anticancer Res., 31, 4569
- Miller W. H., 2002, Cancer Res., 62, 3893
- 10.1097/CJI.0b013e3181755deb · DOI
- Kreuser E. D., 1992, Semin. Oncol., 19, 73
- Magnarin M., 2000, Anticancer Res., 20, 2939
- Nardon C., 2014, Anticancer Res., 34, 487
- Hashimoto K., 1994, J. Rheumatol., 21, 1020
- Yan A., 1990, J. Rheumatol., 17, 47
- Wang X. D., 2009, Zhongguo Shi Yan Xue Ye Xue Za Zhi, 17, 533
- 10.1371/journal.pone.0100933 · DOI · Paper page
- Korbecki J., 2012, Acta Biochim. Polym., 59, 195
- 10.3109/1547691X.2014.996681 · DOI
- Desoize B., 2004, Anticancer Res., 24, 1529
- Sava G., 1985, Anticancer Res., 5, 249
- Boscolo P., 2004, Ann. Clin. Lab. Sci., 34, 299
- Brewer G. J., 2000, Clin. Cancer Res., 6, 1
- Redman B. G., 2003, Clin. Cancer Res., 9, 1666
- Pan Q., 2003, Mol. Cancer Res., 1, 701
- Lukasewycz O. A., 1982, J. Natl. Cancer Inst., 69, 489
- 10.1515/9783110470734-016 · doi:10.1515/9783110470734-016
- Eriksson M., 2009, Anticancer Res., 29, 11
- Signat B., 2011, Curr. Issues Mol. Biol., 13, 25
- Sonis S. T., 2004, J. Support. Oncol., 2, 21
- 10.1053/sonc.2002.35524 · doi:10.1053/sonc.2002.35524 · Paper page
- Juhn S. K., 2001, Int. Tinnitus J., 7, 72
- Boussios S., 2012, Ann. Gastroenterol., 25, 106
- Takeyama K., 2000, Int. J. Hematol., 71, 144
- Giles F. J., 1994, Curr. Opin. Hematol., 1, 256
- Lu J., 2017, Ochsner J., 17, 379
Cited by
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Toxicity of gold nanoparticles (AuNPs): A review
Sani, A., Cao, C., & Cui, D. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.100991 · Cited by 454
Classification of Metal-Based Drugs according to Their Mechanisms of Action
Boros, E., Dyson, P. J., & Gasser, G. (2020) · Chem · doi:10.1016/j.chempr.2019.10.013 · Cited by 437
New Designs for Phototherapeutic Transition Metal Complexes
Imberti, C., Zhang, P., Huang, H., & Sadler, P. J. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201905171 · Cited by 443
The immune microenvironment in cartilage injury and repair
Li, M., Yin, H., Yan, Z., Li, H., Wu, J., Wang, Y., Wei, F., Tian, G., Ning, C., Li, H., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.12.006 · Cited by 403
Metadata
- Authors
- Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W.
- Affiliations
- Comprehensive Cancer Center Vienna (AT)
- University of Vienna (AT)
- Corresponding author
- Berger, Walter
- ORCID
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-11-29
- Volume
- 119
- Issue
- 2
- Pages
- 1519-1624
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2903051221
- Cited by
- 355
- References
- 1,298
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 47 · 2023: 51 · 2022: 49 · 2021: 45 · 2020: 53 · 2019: 38
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Chemical Reviews (publishedVersion)
- PubMed (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Funders
- FP7 People: Marie-Curie Actions (609431)
- Universit?t Wien
- Medizinische Universit?t Wien
- Johanna Mahlke, geb. Obermann-Stiftung zur F?rderung der Krebsforschung an der Universit?t Wien
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- metal-based anticancer agents, antitumor immunity, immune surveillance, immune evasion, cancer immunotherapy, immune checkpoint inhibitors, tumor microenvironment, innate and adaptive immunity
- MeSH terms
- Gastrointestinal Microbiome, Antineoplastic Agents, Humans, Immunity, Innate, Immunotherapy, Lymphocytes, Metals, Neoplasms, Nanoparticles, Coordination Complexes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.